Natera, Inc. (NTRA) stock
NTRANasdaqServices-Medical LaboratoriesFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026Score 10/30152% above fair value
$319.09−3.85 (-1.19%)
Close on Nov 13, 2026Market cap $46.00BP/E –Yield –
Natera EPS
Diluted earnings per share is net income divided by the share count including options and convertible securities.
Natera's EPS for the twelve months ending Sep 30, 2026 was -$1.15. For fiscal 2025 it was -$1.52. The highest annual figure on record is -$1.07 in fiscal 2014.
Annual eps
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$1.52 | – |
| FY2024 | Dec 31, 2024 | -$1.53 | – |
| FY2023 | Dec 31, 2023 | -$3.78 | – |
| FY2022 | Dec 31, 2022 | -$5.57 | – |
| FY2021 | Dec 31, 2021 | -$5.21 | – |
| FY2020 | Dec 31, 2020 | -$2.84 | – |
| FY2019 | Dec 31, 2019 | -$1.79 | – |
| FY2018 | Dec 31, 2018 | -$2.22 | – |
| FY2017 | Dec 31, 2017 | -$2.59 | – |
| FY2016 | Dec 31, 2016 | -$1.95 | – |
| FY2015 | Dec 31, 2015 | -$2.68 | – |
| FY2014 | Dec 31, 2014 | -$1.07 | – |
| FY2013 | Dec 31, 2013 | -$9.66 | – |
Quarterly eps
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -$0.42 | – |
| Q2 FY2026 | Jun 30, 2026 | -$0.47 | – |
| Q1 FY2026 | Mar 31, 2026 | -$0.60 | – |
| Q4 FY2025 | Dec 31, 2025 | $0.34 | – |
| Q3 FY2025 | Sep 30, 2025 | -$0.64 | – |
| Q2 FY2025 | Jun 30, 2025 | -$0.74 | – |
| Q1 FY2025 | Mar 31, 2025 | -$0.50 | – |
| Q4 FY2024 | Dec 31, 2024 | -$0.41 | – |
| Q3 FY2024 | Sep 30, 2024 | -$0.26 | – |
| Q2 FY2024 | Jun 30, 2024 | -$0.30 | – |
| Q1 FY2024 | Mar 31, 2024 | -$0.56 | – |
| Q4 FY2023 | Dec 31, 2023 | -$0.65 | – |
| Q3 FY2023 | Sep 30, 2023 | -$0.95 | – |
| Q2 FY2023 | Jun 30, 2023 | -$0.97 | – |
| Q1 FY2023 | Mar 31, 2023 | -$1.23 | – |
| Q4 FY2022 | Dec 31, 2022 | -$1.37 | – |
| Q3 FY2022 | Sep 30, 2022 | -$1.25 | – |
| Q2 FY2022 | Jun 30, 2022 | -$1.50 | – |
| Q1 FY2022 | Mar 31, 2022 | -$1.45 | – |
| Q4 FY2021 | Dec 31, 2021 | -$1.48 | – |
| Q3 FY2021 | Sep 30, 2021 | -$1.63 | – |
| Q2 FY2021 | Jun 30, 2021 | -$1.32 | – |
| Q1 FY2021 | Mar 31, 2021 | -$0.74 | – |
| Q4 FY2020 | Dec 31, 2020 | -$0.89 | – |
| Q3 FY2020 | Sep 30, 2020 | -$0.72 | – |
| Q2 FY2020 | Jun 30, 2020 | -$0.75 | – |
| Q1 FY2020 | Mar 31, 2020 | -$0.45 | – |
| Q4 FY2019 | Dec 31, 2019 | -$0.46 | – |
| Q3 FY2019 | Sep 30, 2019 | -$0.33 | – |
| Q2 FY2019 | Jun 30, 2019 | -$0.48 | – |
| Q1 FY2019 | Mar 31, 2019 | -$0.54 | – |
| Q4 FY2018 | Dec 31, 2018 | -$0.51 | – |
| Q3 FY2018 | Sep 30, 2018 | -$0.49 | – |
| Q2 FY2018 | Jun 30, 2018 | -$0.62 | – |
| Q1 FY2018 | Mar 31, 2018 | -$0.61 | – |
| Q4 FY2017 | Dec 31, 2017 | -$0.90 | – |
| Q3 FY2017 | Sep 30, 2017 | -$0.52 | – |
| Q2 FY2017 | Jun 30, 2017 | -$0.55 | – |
| Q1 FY2017 | Mar 31, 2017 | -$0.65 | – |
| Q4 FY2016 | Dec 31, 2016 | -$0.72 | – |
- Revenue
- Gross Profit
- Operating Income
- Net Income
- EBITDA
- Free Cash Flow
- Operating Cash Flow
- R&D Expenses
- Gross Margin
- Operating Margin
- Profit Margin
- Total Debt
- Cash
- Total Assets
- Shares Outstanding
- Market Cap
- Enterprise Value
- PE Ratio
- Price to Sales Ratio
- Price to Book Ratio
- EV/EBITDA
- Price to Free Cash Flow
- All statistics
See a number that looks wrong?